<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524210</url>
  </required_header>
  <id_info>
    <org_study_id>1208088</org_study_id>
    <secondary_id>2013-004932-31</secondary_id>
    <secondary_id>140096A-21</secondary_id>
    <nct_id>NCT02524210</nct_id>
  </id_info>
  <brief_title>Effect of Inhibitors of the Proton Pump on Intestinal Transporters</brief_title>
  <acronym>BIPP</acronym>
  <official_title>Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dabigatran etexilate is a novel oral anticoagulant. It is indicated in venous thromboembolic
      prevention in orthopedic surgery and has recently shown greater efficiency and tolerance as
      anticoagulants in preventing thromboembolism in atrial fibrillation. However, it increases
      the risk of gastrointestinal bleeding compared to standard treatment (AVK) [3]. In these
      circumstances the risk / benefit of dabigatran could be improved by combining it with gastric
      protectors such as inhibitor drugs proton pump (IPP).

      Investigators want to evaluate the pharmacokinetic and pharmacodynamic effects of
      co-administration of these two IPP (omeprazole, rabeprazole) with dabigatran in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>baseline after each dose of dabigatran etexilate.</time_frame>
    <description>Area under the curve (AUC) from plasma concentrations of dabigatran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>0.25 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>0.5 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>1 hour after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>1.5 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>2 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>3 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>6 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>8 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>12 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) from plasma concentrations of dabigatran</measure>
    <time_frame>24 hours after each dose of dabigatran etexilate.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; Dabigatran&quot;
Washout period (at least 6 days)
Period &quot; Rabeprazole + Dabigatran&quot;
Washout period (at least 6 days)
Period &quot; Omeprazole + Dabigatran&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot;Rabeprazole + Dabigatran &quot;
Washout period (at least 6 days)
Period &quot; Dabigatran&quot;
Washout period (at least 6 days)
Period &quot; Omeprazole + Dabigatran&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period &quot; Rabeprazole + Dabigatran&quot;
Period &quot; Omeprazole + Dabigatran&quot;
Period &quot; Dabigatran&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>dabigatran etexilate 150 mg/day (1 day)</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole and Dabigatran</intervention_name>
    <description>rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole and Dabigatran</intervention_name>
    <description>omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  weight between 60 and 85 kg

          -  normal clinical exam

          -  normal biological exam

        Exclusion Criteria:

          -  hypersensitivity to dabigatran or any of its excipients

          -  hypersensitivity to omeprazole or rabeprazole or any of its excipients

          -  previous history of hemorrhagic disease

          -  insufficiency liver

          -  severe kidney failure

          -  peptic ulcer

          -  Any drug taken during the week before the start of the study

          -  smoker

          -  Consumption of grapefruit juice

          -  practice of violent sport
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent BERTOLETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de SAINT-ETIENNE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de SAINT-ETIENNE</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2015</study_first_submitted>
  <study_first_submitted_qc>August 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2015</study_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

